AI Engines For more Details: Perplexity Kagi Labs You
Angina Pectoris: Prenylamine lactate is primarily prescribed for the management of angina pectoris, a condition characterized by chest pain or discomfort caused by reduced blood flow to the heart muscle. It works by dilating blood vessels, thereby increasing blood flow to the heart and reducing the frequency and severity of angina episodes.
Vasodilation: Prenylamine lactate exerts its therapeutic effects by inhibiting the entry of calcium ions into vascular smooth muscle cells, leading to relaxation and dilation of blood vessels. This vasodilatory action results in increased coronary blood flow and reduced peripheral resistance, which helps alleviate symptoms of angina and improve myocardial oxygen supply.
Antiarrhythmic Properties: In addition to its vasodilatory effects, prenylamine lactate also exhibits antiarrhythmic properties. It can help stabilize the heart's electrical activity and prevent or control certain types of cardiac arrhythmias, such as ventricular arrhythmias.
Reduction of Myocardial Oxygen Demand: By dilating coronary arteries and improving myocardial perfusion, prenylamine lactate reduces the oxygen demand of the heart muscle. This can be beneficial for individuals with angina or ischemic heart disease, as it helps prevent myocardial ischemia and reduces the risk of heart attacks.
Hypotension: Prenylamine lactate may cause a decrease in blood pressure, especially when administered at higher doses or in individuals with pre-existing hypotension. Patients should be monitored for signs of low blood pressure, such as dizziness, lightheadedness, or fainting.
Bradycardia: In some cases, prenylamine lactate may cause a slowing of the heart rate (bradycardia). This effect may be more pronounced in individuals with underlying cardiac conduction abnormalities or those taking other medications that affect heart rate. Regular monitoring of heart rate is recommended during treatment with prenylamine lactate.
Contraindications: Prenylamine lactate is contraindicated in patients with severe hypotension, cardiogenic shock, second- or third-degree atrioventricular block, sick sinus syndrome, and other significant cardiac conduction disturbances. It should also be used with caution in individuals with hepatic impairment or a history of heart failure.
Drug Interactions: Prenylamine lactate may interact with other medications that affect cardiac conduction or blood pressure, such as beta-blockers, antiarrhythmics, and vasodilators. Concurrent use of these agents should be carefully monitored to avoid adverse effects or excessive cardiovascular depression.
Side Effects: Common side effects associated with prenylamine lactate may include headache, dizziness, flushing, gastrointestinal disturbances, and peripheral edema. Serious adverse effects such as heart block, syncope, or allergic reactions are rare but may occur.
Pregnancy and Lactation: The safety of prenylamine lactate use during pregnancy and breastfeeding has not been well-established. It should be used with caution in pregnant or nursing women, and the potential risks and benefits should be carefully weighed.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| ADHD | 2.4 | 0.3 | 7 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.1 | 1.5 | 1.07 |
| Allergies | 3.5 | 1.4 | 1.5 |
| Allergy to milk products | 1.4 | 1.3 | 0.08 |
| Alopecia (Hair Loss) | 1.3 | 1.3 | |
| Alzheimer's disease | 4.5 | 5.8 | -0.29 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.7 | 0.6 | 3.5 |
| Ankylosing spondylitis | 4 | 1.5 | 1.67 |
| Anorexia Nervosa | 1.1 | 2.6 | -1.36 |
| Antiphospholipid syndrome (APS) | 2.1 | 0.3 | 6 |
| Asthma | 4.4 | 1.1 | 3 |
| Atherosclerosis | 1.8 | 1.3 | 0.38 |
| Atrial fibrillation | 3.2 | 2.8 | 0.14 |
| Autism | 7.3 | 8.4 | -0.15 |
| Autoimmune Disease | 0.9 | 0.7 | 0.29 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.5 | 2.5 | |
| Bipolar Disorder | 1.8 | 0.8 | 1.25 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Breast Cancer | 1 | 1 | |
| Cancer (General) | 0.3 | 0.8 | -1.67 |
| Carcinoma | 3.3 | 1.4 | 1.36 |
| Celiac Disease | 3 | 2 | 0.5 |
| Cerebral Palsy | 0.8 | 1 | -0.25 |
| Chronic Fatigue Syndrome | 3.6 | 5.4 | -0.5 |
| Chronic Kidney Disease | 3 | 2.3 | 0.3 |
| Chronic Lyme | 0.2 | 0.8 | -3 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.7 | 1.7 | 0.59 |
| Chronic Urticaria (Hives) | 1.7 | 1.2 | 0.42 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1 | 0.9 |
| Cognitive Function | 1.7 | 1 | 0.7 |
| Colorectal Cancer | 6.8 | 2.2 | 2.09 |
| Constipation | 1.8 | 0.7 | 1.57 |
| Coronary artery disease | 2.4 | 2.5 | -0.04 |
| COVID-19 | 5.6 | 8.2 | -0.46 |
| Crohn's Disease | 8 | 4.6 | 0.74 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1 | 0.2 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.5 | 1.1 | 1.27 |
| Denture Wearers Oral Shifts | 1.3 | 1.3 | |
| Depression | 9 | 7.2 | 0.25 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 2 | 1.7 | 0.18 |
| Endometriosis | 3.2 | 1.7 | 0.88 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 3 | 1.5 | 1 |
| erectile dysfunction | 1.4 | 1.4 | |
| Fibromyalgia | 2.5 | 2.3 | 0.09 |
| Functional constipation / chronic idiopathic constipation | 4.8 | 3.4 | 0.41 |
| gallstone disease (gsd) | 3.7 | 0.8 | 3.63 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.9 | 0.7 | 1.71 |
| Generalized anxiety disorder | 3.1 | 1.1 | 1.82 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.5 | 0.2 |
| Graves' disease | 0.7 | 2.1 | -2 |
| Gulf War Syndrome | 0.9 | 1.2 | -0.33 |
| Halitosis | 1.3 | 0.3 | 3.33 |
| Hashimoto's thyroiditis | 2.7 | 1.2 | 1.25 |
| Heart Failure | 4.6 | 1.3 | 2.54 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 1.4 | |
| High Histamine/low DAO | 1.6 | 1.6 | |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.8 | |
| hyperglycemia | 1.8 | 0.9 | 1 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.5 | 3.9 | -0.11 |
| Hypothyroidism | 0.4 | -0.4 | |
| Hypoxia | 2.9 | 2.9 | |
| IgA nephropathy (IgAN) | 1.3 | 3.7 | -1.85 |
| Inflammatory Bowel Disease | 6.2 | 7 | -0.13 |
| Insomnia | 2.2 | 1.8 | 0.22 |
| Intelligence | 2 | 0.6 | 2.33 |
| Intracranial aneurysms | 1.1 | 0.3 | 2.67 |
| Irritable Bowel Syndrome | 5.8 | 3.5 | 0.66 |
| ischemic stroke | 1.7 | 1.7 | 0 |
| Liver Cirrhosis | 6.2 | 3.4 | 0.82 |
| Long COVID | 5.6 | 4.8 | 0.17 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 0.7 | 0.29 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.3 | 0.3 | 3.33 |
| ME/CFS with IBS | 1 | 1.3 | -0.3 |
| ME/CFS without IBS | 1.1 | 1.7 | -0.55 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 6.3 | 5.4 | 0.17 |
| Mood Disorders | 7.4 | 5.7 | 0.3 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 4.8 | 5.6 | -0.17 |
| Multiple system atrophy (MSA) | 0.8 | 0.1 | 7 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 1.8 | -1.8 | |
| Neuropathy (all types) | 0.4 | 1.6 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.4 | 2.3 | 0.91 |
| NonCeliac Gluten Sensitivity | 0.4 | 0.3 | 0.33 |
| Obesity | 6.8 | 6.2 | 0.1 |
| obsessive-compulsive disorder | 4.7 | 3.4 | 0.38 |
| Osteoarthritis | 2.7 | 0.6 | 3.5 |
| Osteoporosis | 1.6 | 1.3 | 0.23 |
| pancreatic cancer | 0.7 | 0.3 | 1.33 |
| Parkinson's Disease | 5.4 | 6.5 | -0.2 |
| Polycystic ovary syndrome | 6.2 | 1.7 | 2.65 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.1 | 0.4 | -3 |
| primary biliary cholangitis | 0.9 | 1.4 | -0.56 |
| Primary sclerosing cholangitis | 2.1 | 2.4 | -0.14 |
| Psoriasis | 2.1 | 3.4 | -0.62 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.6 | 3.5 | 0.6 |
| Rosacea | 0.3 | 0.7 | -1.33 |
| Schizophrenia | 3.3 | 2.2 | 0.5 |
| scoliosis | 0.9 | 0.9 | 0 |
| Sjögren syndrome | 2 | 2.3 | -0.15 |
| Sleep Apnea | 1.6 | 1.3 | 0.23 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.9 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 2 | |
| Stress / posttraumatic stress disorder | 2.9 | 1.6 | 0.81 |
| Systemic Lupus Erythematosus | 4 | 1.3 | 2.08 |
| Tic Disorder | 0.9 | 1.2 | -0.33 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3.3 | 2.2 | 0.5 |
| Type 2 Diabetes | 7.3 | 6.1 | 0.2 |
| Ulcerative colitis | 5.3 | 5.5 | -0.04 |
| Unhealthy Ageing | 5.4 | 1.9 | 1.84 |
| Vitiligo | 1.9 | 1.2 | 0.58 |
